Biocon Q4 Results

Analysts estimate 38 per cent annual growth in earnings during FY20-22

In a Q&A, Biocon CEO and MD Siddharth Mittal explains why he believes his company is on track to achieve the $1 billion revenue target from the segment by 2022

The net profit for the period declined 42.2 per cent to Rs 123 crore on YoY basis, according to a BSE filing by the company

Strong performance owing to growth in biologics, research services and small molecules business, says company